Identification of Quality Markers in Schisandra chinensis (Turcz.) Baill. Using UPLC-Q-Extractive Orbitrap/MS, Chemometric Analysis, and Network Pharmacology

Yinpeng Wang,Yumei Li,Yan Ding,Xinxin Du,Jingbo Zhu

DOI: https://doi.org/10.3390/separations11030088

2024-03-18

Separations

Abstract:Chemical composition is a critical factor for determining the efficacy of any traditional Chinese medicine (TCM) and can be used as an indicator of commercial quality. To develop a new strategy for discovering potential quality markers (Q-markers) of TCM by integrating ultra-performance liquid chromatography-Q-extractive orbitrap/mass spectrometry (UPLC-Q-Extractive Orbitrap/MS), chemometric analysis, and network pharmacology, using Schisandra chinensis (Turcz.) Baill. (S. chinensis) as an example. The chemical profiling of S. chinensis was performed using UPLC-Q-Extractive Orbitrap/MS, followed by identification of hepatoprotective Q-markers through a comprehensive understanding of chemometric analysis and virtual target prediction of network pharmacology. Six compounds were considered potent candidates for Q-markers, which were identified as schisandrol A (6), angeloylgomisin H (10), schisantherin A (17), schisantherin B (18), schisandrin A (23), and schisandrin C (26). All Q-markers exhibited significant hepatoprotective activity, as evidenced by in vitro experiments. Subsequently, a method for simultaneous quantification was established and employed to analyse seven batches of S. chinensis. Therefore, the integrated approach of UPLC-Q-Extractive Orbitrap/MS, chemometrics, and network pharmacology proved to be an effective strategy for the discovery of Q-markers that can assist in assessing the overall chemical consistency of samples and provide a basis for quality evaluation of the material basis of S. chinensis.

chemistry, analytical

What problem does this paper attempt to address?

The paper aims to address the quality control issues of traditional Chinese medicine Schisandra chinensis. Specifically, the authors attempt to identify potential quality markers (Q-markers) in Schisandra chinensis by combining ultra-high-performance liquid chromatography-mass spectrometry (UPLC-Q-Extractive Orbitrap/MS), chemometric analysis, and network pharmacology methods to improve the comprehensiveness and accuracy of its quality assessment.

### Background
Schisandra chinensis is a traditional Chinese medicine widely used for treating liver diseases, neurological disorders, and immune modulation. However, traditional quality control methods often rely on a single or a few indicators, which may not fully reflect the complex chemical composition of Schisandra chinensis. Additionally, issues such as adulteration and compositional changes due to different growth stages are pressing problems in the current quality control of Schisandra chinensis.

### Research Objectives
1. **Identify potential quality markers**: Identify key active components in Schisandra chinensis that can serve as quality markers by comprehensively using UPLC-Q-Extractive Orbitrap/MS, chemometric analysis, and network pharmacology methods.
2. **Evaluate chemical consistency**: Ensure the stability and consistency of the chemical composition of Schisandra chinensis by conducting an overall assessment of the chemical characteristics of different batches of samples.
3. **Provide a basis for quality evaluation**: Provide scientific evidence for the quality control of Schisandra chinensis to ensure the correlation between its clinical efficacy and quality.

### Methods
1. **Sample preparation and analysis**: Use UPLC-Q-Extractive Orbitrap/MS to analyze the chemical components of Schisandra chinensis samples, detecting 36 compounds, including 23 lignans, 4 flavonoids, 3 triterpenoids, 3 phenolic acids, 2 organic acids, and 1 nitrogen-containing compound.
2. **Chemometric analysis**: Classify and differentiate Schisandra chinensis samples at different maturity stages through principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), and screen out key compounds.
3. **Network pharmacology analysis**: Predict the bioavailability and drug-likeness of the compounds, identify potential targets through target prediction platforms, and construct a compound-target-disease network.
4. **Molecular docking**: Verify the binding ability of key compounds to targets through molecular docking technology.
5. **In vitro experiments**: Evaluate the hepatoprotective activity of key compounds using the BRL-3A cell line.

### Results
1. **Chemical composition identification**: A total of 36 compounds were detected, among which 23 lignans were considered the main active components.
2. **Chemometric analysis**: PCA and OPLS-DA analysis results showed significant differences in the chemical composition of Schisandra chinensis samples at different maturity stages, especially the distribution of the 1st group (R1) samples on the PC2 axis, indicating it as a critical time point.
3. **Network pharmacology analysis**: Four compounds with high bioavailability and drug-likeness (schisandrol A, angeloylgomisin H, schisantherin A, and schisandrin A) were screened out, showing significant effects in hepatoprotective activity.
4. **Molecular docking and in vitro experiments**: Molecular docking results showed good binding ability of these compounds to targets, and in vitro experiments further confirmed their hepatoprotective activity.

### Conclusion
By combining UPLC-Q-Extractive Orbitrap/MS, chemometric analysis, and network pharmacology methods, this study successfully identified potential quality markers in Schisandra chinensis and provided scientific evidence for its quality control. These markers not only help assess the overall chemical consistency of Schisandra chinensis but also provide reliable quality assurance for clinical applications.